Key result
The CT/TT genotypes at the LRP5 rs2306862 locus significantly increased the risk of abnormal bone mass compared to the CC genotype in postmenopausal women with type 2 diabetes (OR 2.434).
Why the study?
Previous work linked LRP5 and LRP6 loci to abnormal bone mass (ABM) in postmenopausal women with T2DM, motivating an investigation into the role of LRP5-LRP6 SNPs and gene-gene and gene-environment interactions in ABM development.
Are LRP5 and LRP6 gene polymorphisms and their interactions associated with the risk of abnormal bone mass in postmenopausal women with type 2 diabetes mellitus?
Case-Control (n=272)
No
Are LRP5 and LRP6 gene polymorphisms and their interactions associated with the risk of abnormal bone mass in postmenopausal women with type 2 diabetes mellitus?
Odds Ratio: 2.434 (95% CI 1.071–5.531)
p-value: p=0.034
LRP5 and LRP6 polymorphisms, along with gene-gene and gene-age interactions, are associated with an increased risk of abnormal bone mass in postmenopausal women with type 2 diabetes.
CT/TT genotypes at LRP5 rs2306862 were associated with higher abnormal bone mass risk; hypothesis-generating and requires prospective validation before any clinical use.
Background: A previous work has discovered that LRP5 and LRP6 locus are linked to the risk of ABM in postmenopausal women with type 2 diabetes mellitus (T2DM). This study aimed to investigate the role of LRP5-LRP6 SNP and gene-gene and gene-environment interactions in the development of ABM in postmenopausal women with type 2 diabetes mellitus . Methods: A total of 272 postmenopausal women, comprising 166 patients with abnormal bone mass (ABM) and 106 controls with normal bone mass, were recruited based on BMD results. BMD of the lumbar spine 1-4 (L1-4) and femoral neck (FN) was measured by dual-energy X-ray (DEXA), and polymorphisms and gene frequency distributions of LRP5 rs2306862, rs41494349, and LRP6 rs10743980, rs2302685 were determined by time-of-flight mass spectrometry (MALDI-TOF MS). Results: 1) Logistic regression analysis showed that the risk of ABM was higher for the CT and CT/TT genotypes than for the CC genotype at the rs2306862 locus of the LRP5 gene (OR=2.353, 95%CI=1.039-6.186; OR=2.434, 95%CI=1.071, 5.531; P <0.05). TC genotype at the rs2302685 locus of the LRP6 gene has a higher risk of ABM than TT genotype (OR=2.951, 95%CI=1.030-8.457, P <0.05). 2) Polymorphisms at the rs2306862&rs10743980, rs41494349&rs2302685&rs10743980 SNPs were synergistic with the development of ABM and were risk factors for the development of ABM ( P <0.05). Polymorphisms at rs2306862, rs2302685, rs41494349&rs2302685& rs10743980 SNPs were synergistic with the occurrence of ABM and were risk factors for the occurrence of ABM ( P <0.05). There was an interaction between gene polymorphism & age at each locus at menopause and the occurrence of ABM ( P >0.05). Conclusion: These findings indicate that LRP5-rs2306862 and LRP6-rs2302685 polymorphisms, gene-gene, and gene-age interactions are associated with an increased risk of ABM in postmenopausal women with type 2 diabetes mellitus.
No takes yet. Share an insight, caveat, or question.
Li et al. (2023) conducted a case-control in Abnormal bone mass in type 2 diabetes mellitus (n=272). LRP5 rs2306862 CT/TT genotype vs. LRP5 rs2306862 CC genotype was evaluated on Risk of abnormal bone mass (ABM) (OR 2.434, 95% CI 1.071-5.531, p=0.034). The CT/TT genotypes at the LRP5 rs2306862 locus significantly increased the risk of abnormal bone mass compared to the CC genotype in postmenopausal women with type 2 diabetes (OR 2.434).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: